{"filing":{"accession_number":"0001193125-26-429533","cik":"0001717115","ticker":"TEM","company_name":"Tempus AI, Inc.","form":"8-K","filing_date":"2026-10-23","report_date":"2026-10-23","primary_document":"d135568d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1717115/000119312526429533/d135568d8k.htm"},"events":[{"id":37469,"run_id":34538,"accession_number":"0001193125-26-429533","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Tempus announced a series of material commercial agreements with Bristol-Myers Squibb and Pathos AI totaling $192.5 million in aggregate cash payments over five years. The disclosure covers licensing of de-identified oncology and neurology data, software tools, and related services—a significant strategic partnership and revenue-generating arrangement. While this is a material operational and commercial event, it does not fit the specific categories of M\u0026A activity, debt issuance, or other named financial events; it is best classified as a material operational/strategic business arrangement.","company_name":"Tempus AI, Inc.","ticker":"TEM","filing_date":"2026-10-23","form":"8-K","submitted_at":null,"items":[{"id":42190,"accession_number":"0001193125-26-429533","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Tempus announced a series of material commercial agreements with Bristol-Myers Squibb and Pathos AI totaling $192.5 million in aggregate cash payments over five years. The disclosure covers licensing of de-identified oncology and neurology data, software tools, and related services—a significant strategic partnership and revenue-generating arrangement. While this is a material operational and commercial event, it does not fit the specific categories of M\u0026A activity, debt issuance, or other named financial events; it is best classified as a material operational/strategic business arrangement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T13:01:46.905759+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42190,"accession_number":"0001193125-26-429533","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Tempus announced a series of material commercial agreements with Bristol-Myers Squibb and Pathos AI totaling $192.5 million in aggregate cash payments over five years. The disclosure covers licensing of de-identified oncology and neurology data, software tools, and related services—a significant strategic partnership and revenue-generating arrangement. While this is a material operational and commercial event, it does not fit the specific categories of M\u0026A activity, debt issuance, or other named financial events; it is best classified as a material operational/strategic business arrangement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T13:01:46.905759+00:00","company_name":"Tempus AI, Inc.","ticker":"TEM","filing_date":"2026-10-23"}]}